Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia  | Date: 2021-04-06

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical trials displayed promising outcome.

The pharmaceutical firm said that in its Phase 3 trials, more than 91.15% of patients administered with PegIFN PegiHepTM, had an RT-PCR negative result by the seventh day, in comparison to 78.90% of patients treated with SOC (standard of care) arm.

In the case of moderate COVID-19 patients, the medication decreased the period of additional oxygen from 84 hours to 56 hours. This shows that it was able to manage respiratory distress and failure, which has been one of the most difficult aspects of managing COVID-19, the company added.

It is worth noting that the drug has a well-established record of safety, with several doses being given to chronic hepatitis B and C patients for several years.

Aging decreases the ability of the body to generate Interferon Alpha which helps in responding to viral infections, further increasing the risk of death among elderly individuals. Pegylated Interferon Alpha 2b, provided at an early stage of the infection, can compensate for this deficiency and speed up recovery.

The preliminary findings suggest that, if given early, PegIFN can help in faster recovery of patients and prevent many of the problems seen in later stages of the disease. Since it is a single-dose regimen, the treatment would be less difficult and more affordable, Zydus said.

Dr. Sharvil Patel, Managing Director at Cadila Healthcare Ltd., reportedly said that they are motivated by the Phase III results of the PegIFN study which has shown the potential to decrease the impact of the virus when given in the early stage of the disease.

In addition to performing a Phase-II trial in Mexico, the company is collaborating with the USFDA on Pegylated Interferon clinical trials in the United States, sources with relevant information cited.

Source Credit –

https://www.businesstoday.in/current/corporate/zydus-covid-19-drug-shows-promise-phase-3-trials-seeks-dcgi-nod/story/435729.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

ZeroAvia buys HyPoint to strengthen hydrogen fuel-cell technology offering

ZeroAvia buys HyPoint to strengthen hydrogen fuel-cell technology offering

By Nikita Chaurasia

British/American hydrogen-electric aircraft developer, ZeroAvia has wholly purchased HyPoint, a hydrogen fuel cell system provider, to strengthen its hydrogen-electric product portfolio. As per sources, ZeroAvia is developing powertrains for hydro...

Chanel pioneers ¬sustainability-linked bonds for combating climate changes

Chanel pioneers ¬sustainability-linked bonds for combating climate changes

By Nikita Chaurasia

French luxury fashion house well-recognized for its perfumes and tweed suits, Chanel, has reportedly unveiled ­sustainability-linked bonds, or SLBs, to combat climate change two years ago when the firm was in need to borrow money. The investor...

NLP Logix Partners and Databricks team up for Lakehouse Platform

NLP Logix Partners and Databricks team up for Lakehouse Platform

By Nikita Chaurasia

NLP Logix, a well-known predictive modeling and machine learning leader, has recently announced that it has entered into a partnership with Databricks, an American enterprise software company, to drive business value by deploying data and artificial ...

Elliptic Labs inks deal with Xiaomi to offer a proximity detection solution

Elliptic Labs inks deal with Xiaomi to offer a proximity detection solution

By Nikita Chaurasia

Elliptic Labs, a global AI software company, has reportedly entered into a new agreement with Xiaomi, one of the third-largest smartphone manufacturers across the globe. With this agreement, Xiaomi will continue to leverage INNER BEAUTY, the AI Vi...

L&T Technology Services partners with Qualcomm to amplify 5G adoption

L&T Technology Services partners with Qualcomm to amplify 5G adoption

By Nikita Chaurasia

L&T Technology Services Limited has recently announced that it is teaming up with Qualcomm Technologies, Inc., the world’s leading wireless technology innovator. With the latest collaboration, the firm plans to offer end-to-end solutions...